English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The mortality associated with unresectable or metastatic melanoma remains high despite of the emergence of new anti-tumor agents. In this case report, we present two metastatic melanoma patients with copy number variations (CNVs) of cyclin dependent kinase 4 (CDK4) pathway-related genes, who had failed in previous chemotherapy or immunotherapy, were treated with CDK4/6 inhibitor palbociclib and achieved tumor control for over 6 months. The copy number of CDK4, CCND1 and P16INK4a of one patient was 3.6, 3, 2 copies, and for the other patient, the copy number was 3, 2, 1 respectively. It indicates that CDK4 may be a potential target for melanoma.

Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report